Shares of Verona Pharma PLC American Depositary Share (NASDAQ:VRNA) have earned a consensus broker rating score of 1.00 (Strong Buy) from the four analysts that cover the stock, Zacks Investment Research reports. Four equities research analysts have rated the stock with a strong buy recommendation.

Brokers have set a 12 month consensus price target of $26.75 for the company, according to Zacks. Zacks has also given Verona Pharma PLC American Depositary Share an industry rank of 103 out of 265 based on the ratings given to its competitors.

A number of research analysts recently issued reports on VRNA shares. Zacks Investment Research upgraded Verona Pharma PLC American Depositary Share from a “hold” rating to a “buy” rating and set a $14.00 price target on the stock in a research note on Tuesday, July 25th. Wedbush restated an “outperform” rating and set a $33.00 price target on shares of Verona Pharma PLC American Depositary Share in a research note on Friday, September 8th.

Shares of Verona Pharma PLC American Depositary Share (NASDAQ VRNA) traded up 0.06% during midday trading on Thursday, hitting $15.51. The stock had a trading volume of 1,887 shares. Verona Pharma PLC American Depositary Share has a one year low of $11.03 and a one year high of $17.50. The firm has a 50 day moving average price of $14.25 and a 200 day moving average price of $13.92. The stock’s market cap is $203.60 million.

Verona Pharma PLC American Depositary Share (NASDAQ:VRNA) last released its quarterly earnings results on Tuesday, August 8th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.09). On average, equities analysts forecast that Verona Pharma PLC American Depositary Share will post ($2.23) earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “Zacks: Verona Pharma PLC American Depositary Share (VRNA) Given $26.75 Average Price Target by Brokerages” was published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this article on another website, it was stolen and republished in violation of U.S. & international copyright and trademark legislation. The legal version of this article can be accessed at https://www.thecerbatgem.com/2017/10/05/zacks-verona-pharma-plc-american-depositary-share-vrna-given-26-75-average-price-target-by-brokerages.html.

Hedge funds have recently made changes to their positions in the business. Vivo Capital LLC purchased a new position in shares of Verona Pharma PLC American Depositary Share in the 2nd quarter valued at approximately $8,208,000. Tekla Capital Management LLC purchased a new position in shares of Verona Pharma PLC American Depositary Share in the 2nd quarter valued at approximately $3,211,000. Finally, FIL Ltd purchased a new position in shares of Verona Pharma PLC American Depositary Share in the 2nd quarter valued at approximately $873,000. Institutional investors own 30.16% of the company’s stock.

About Verona Pharma PLC American Depositary Share

Verona Pharma plc, a clinical stage biopharmaceutical company, researches, discovers, and develops therapeutic drugs to treat respiratory diseases primarily in the United Kingdom and North America. The company’s lead product is RPL554, an inhaled dual inhibitor of the enzymes phosphodiesterase 3 and 4, which is in Phase IIa clinical trial that acts as a bronchodilator and an anti-inflammatory agent for the treatment of chronic obstructive pulmonary disease, cystic fibrosis, and asthma.

Get a free copy of the Zacks research report on Verona Pharma PLC American Depositary Share (VRNA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Stock Ratings for Verona Pharma PLC American Depositary Share Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verona Pharma PLC American Depositary Share and related stocks with our FREE daily email newsletter.